September 28, 2023
The New York Times: Could a Nasal Spray Help Protect You From Covid?
Nitric oxide is perhaps the best-studied antimicrobial. Initially, it was tested as a
treatment for Covid; studies conducted in England and India showed that a nitric oxide
nasal spray reduced levels of the virus in people with mild infections faster than a
placebo.
March 14, 2023
Jerusalem Post: Business Innovation
Israeli-Canadian start-up SaNOtize set up a booth at February’s OurCrowd Global Summit to test its antiviral spray, enovid. The company’s co-founder and chief science officer, Chris Miller, told me this was “the world’s first double-blind clinical trial launched at a convention.”
February 23, 2023
Interview with Medium: Gilly Regev of SaNOtize
Our CEO Gilly Regev is featured in Medium’s series “Why We Need More Women Founders,” in which she discusses the story of SaNOtize and the challenges she overcame to get to where she is today.
January 5, 2023
MedCity News: The Power of Nitric Oxide
While more work needs to be done, the current research into new delivery platforms for nitric oxide is extremely promising.
January 3, 2023
The Jerusalem Post
While more work needs to be done, the current research into new delivery platforms for nitric oxide is extremely promising. We hope to see the molecule play an increasingly prominent role in treatment and prevention strategies for common infections – and in so doing help provide greater access to healthcare globally.
Can an anti-viral nasal spray stop Corona and other viruses?
September 15, 2022
FierceLifeSciences: Nitric Oxide Nasal Spray (NONS™) shortlisted as finalist for the Fierce Innovation Awards: Life Sciences Edition 2022
Nitric Oxide Nasal Spray (NONS™) has been shortlisted as one of the finalists for the Fierce Innovation Awards: Life Sciences Edition 2022
August 30, 2022
FiercePharma: SaNOtize Raises $24M Series B
SaNOtize has raised a $24 million series B round, giving it the cash to fund its ongoing phase 3 COVID-19 prevention trial and other research into its nitric oxide nasal spray (NONS).
SaNOtize bags $24M to fund phase 3 trial of COVID-19 nasal spray
July 25, 2022
FierceBiotech: SaNOtize seeks OTC Market
There are currently zero authorized or approved preventative COVID therapies in the U.S. but Canadian biotech SaNOtize wants to change that, charting plans to move a nasal spray into a phase 3 study as soon as October.
As COVID market narrows, SaNOtize moves to carve a new one: over-the-counter prevention
June 27, 2022
PharmaVoice: From vineyards to antivirals, Gilly Regev brings creative thinking to science
The CEO of SaNOtize is tapping into outside-the-box innovation to develop a nitric oxide-delivery platform to treat and prevent COVID-19.
From vineyards to antivirals, Gilly Regev brings creative thinking to science
June 16, 2022
FierceBiotech: Women in Biotech
SaNOtize CEO Dr. Gilly Regev speaks to the emerging progress in diversity and work still to be done in the biotech industry.
February 23, 2022
NoCamels- Phase 3 Results
An Israeli-founded company in Canada developing a nasal technology to treat and prevent upper respiratory and topical infections, like COVID-19, announced that its nasal spray product was approved for sale in India this month after successful Phase 3 clinical trials proved it can reduce viral load in people with mild cases of the novel coronavirus.
SaNOtize Nasal Spray Wins Approval as Early Treatment Option of COVID-19
Fortune India
SaNOtize CEO and co-founder Gilly Regev mentions the company’s anti-coronavirus nasal spray holds an edge over antiviral pills as it can be used daily, something which is not possible with the latter option. The spray, which uses nitric oxide to kill the virus, can reduce the viral load by 99% in 48 hours.
Nasal spray intended for Covid prevention in the future: SaNOtize CEO
February 1, 2022
SaNOtize & Glenmark obtain approval for NONS in India
- The Globe and Mail — Canadian company SaNOtize’s COVID-19 treatment wins approval in India
- Vancouver Sun — COVID-19: B.C.-based biotech companies receive approval in India, U.S. for treatments
- The Telegraph — COVID Nasal Spray halves time until negative PCR
- TrialSite News — Nasal Spray Kills COVID-19, Now Approved in India & Israel Bahrain Indonesia & Thailand: No Mention in Big Media
January 20, 2022
Kyodo News PRWire
Cytori plans to start consulting on pharmaceutical affairs strategies with the Pharmaceuticals and Medical Devices Agency (PMDA), aiming for early approval of Nitric Oxide Nasal Spray (“NONS™”), a preventive and therapeutic drug for COVID-19 infection.
January 18, 2022
RM Indonesia
Enovid nose sanitizer containing nitric oxide has an important role as antiviral and antimicrobial in the nasal cavity and throat cavity, launches in Indonesia.
December 21, 2021
Video: SaNOtize CEO Dr. Gilly Regev in Thailand to collaborate on a clinical study with SWU.
September 22, 2021
Best Health Mag
Multiple companies, including Canada’s SaNOtize, are developing nasal sprays that could change how we fight the virus. Here’s what you need to know:
Could Protection from COVID Soon Be Available Through a Nasal Spray?
August 27, 2021
Inn Why Thailand
A nasal spray for the prevention and elimination of viral nasal and throat viruses under the brand VirX, manufactured by SaNOtize is to be imported to sell in Thailand.
August 10, 2021
Channel 3, Bangkok
August 5, 2021
Alayam.com
The National Health Regulatory Authority has granted certification for the classification of the spray as a medical device, which was developed by Canada-based SaNOtize, as a patented technology of the spray containing nitric oxide, which has proven antimicrobial properties that have been used to treat a variety of diseases including bacterial, fungal and viral infections.